Search
Mesmulogene ancovacivec
go.drugbank.com/drugs/DB06584Investigationalwith MVA-MUC1-IL2 vaccine may stimulate the host immune system to mount a humoral and cytotoxic T lymphocyte (CTL) responses against tumor cells expressing MUC1, a tumor associated antigen, resulting in
Tinoridine
go.drugbank.com/drugs/DB13001InvestigationalTinoridine is under investigation in clinical trial NCT01224756 (Efficacy of Tinoridine in Treating Pain and Inflammation in Adults).
Isuzinaxib
go.drugbank.com/drugs/DB19109InvestigationalIsuzinaxib is under investigation in clinical trial NCT05758896 (Study of APX-115 in Contrast Induced Acute Kidney Injury in Subjects Undergoing PCI).
Ceralasertib
go.drugbank.com/drugs/DB14917InvestigationalCeralasertib is under investigation in clinical trial NCT03682289 (Phase II Trial of AZD6738 Alone and in Combination With Olaparib).
Navicixizumab
go.drugbank.com/drugs/DB12634InvestigationalNavicixizumab is under investigation in clinical trial NCT02298387 (A Phase 1 Study of Navicixizumab in Subjects With Solid Tumors).
Etokimab
go.drugbank.com/drugs/DB16661InvestigationalEtokimab is under investigation in clinical trial NCT03614923 (Etokimab in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps (Crswnp)).
Zagotenemab
go.drugbank.com/drugs/DB16674InvestigationalZagotenemab is under investigation in clinical trial NCT03518073 (A Study of LY3303560 in Participants With Early Symptomatic Alzheimer's Disease).
Lirentelimab
go.drugbank.com/drugs/DB16728InvestigationalLirentelimab is under investigation in clinical trial NCT04856891 (A Study of Lirentelimab (AK002) in Patients With Active Eosinophilic Duodenitis).
Surufatinib
go.drugbank.com/drugs/DB15106InvestigationalSurufatinib is under investigation in clinical trial NCT02588170 (Phase III Study of Surufatinib in Treating Advanced Extrapancreatic Neuroendocrine Tumors).
Olorofim
go.drugbank.com/drugs/DB15245InvestigationalOlorofim is under investigation in clinical trial NCT03340597 (Assessment of Varying Oral Dosing Regimens for F901318 in Healthy Subjects).